Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

And van Goor, who has led development of CF drugs at Vertex since 2001 has warned that there is still much work to do to find ways to correct all the different mutations that lead to the disease.

Vertex has a strong pain management pipeline, which is likely to help the company emerge as one of the largest players in this market. The CF drug portfolio is the foundation on which Vertex can ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

Vertex missed Wall Street's Q1 estimates and announced a pause with an early-stage study of its mRNA cystic fibrosis drug. However, the big drugmaker had plenty of good news in its Q1 update ...

Though Vertex revenues come mostly from its CF franchise, investor focus on the first-quarter call was on the performance of its newer drugs, which were approved in the past year. Vertex gained ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Vertex Pharmaceuticals was known for discovering blockbuster hepatitis C drug Incivek, which is now overshadowed by the company's robust cystic fibrosis franchise. Vertex's approved cystic ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday, due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta. However, the drugmaker ...